Brought to you by 
BMS, Karolinska Institute in cancer collaboration
30 Nov 2021
Executive Summary
Bristol-Myers Squibb and the Karolinska Institute will collaborate, for three years, to apply pharmacogenomics to clinical trial programs in cancer with the goal of personalizing treatment to increase efficacy and decrease side effects. It is the first time a major clinical trial center is participating in an integrated cancer pharmacogenomics program combining both new and existing therapies.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS, Karolinska Institute in cancer collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice